SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254.
  • Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P et al. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132: 104106.
  • Berger BD (1972). Conditioning of food aversions by injections of psychoactive drugs. J Comp Physiol Psychol 81: 2126.
  • Bifulco M, Pisanti S (2009). End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat Rev Drug Discov 8: 594.
  • Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ (2004). Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24: 27082715.
  • Carai MA, Colombo G, Gessa GL, Yalamanchili R, Basavarajappa BS, Hungund BL (2006). Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol 148: 10431050.
  • Chambers AP, Sharkey KA, Koopmans HS (2004). Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 82: 863869.
  • Chambers AP, Koopmans HS, Pittman QJ, Sharkey KA (2006). AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol 147: 109116.
  • Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ et al. (2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293: R2185R2193.
  • Chen RZ, Frassetto A, Lao JZ, Huang RR, Xiao JC, Clements MJ et al. (2008). Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 584: 338342.
  • Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: L113L117.
  • Cottrell GT, Ferguson AV (2004). Sensory circumventricular organs: central roles in integrated autonomic regulation. Regul Pept 117: 1123.
  • De Vry J, Schreiber R, Eckel G, Jentzsch KR (2004). Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 483: 5563.
  • Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F et al. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153: 12721280.
  • Dockray GJ (2009). The versatility of the vagus. Physiol Behav 97: 531536.
  • Fichna J, Schicho R, Andrews CN, Bashashati M, Klompus M, McKay DM et al. (2009). Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil 21: 1326e128.
  • Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497509.
  • Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I et al. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 96129617.
  • Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003). Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462: 125132.
  • Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F (2000). Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 129: 16271632.
  • Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F et al. (2009). Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 158: 451461.
  • Janero DR, Makriyannis A (2009). Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14: 4365.
  • Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 1413614141.
  • Jarbe TU, DiPatrizio NV (2005). Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav Pharmacol 16: 373380.
  • Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769776.
  • Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334: R1R2.
  • LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S et al. (2009). Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 19: 639643.
  • McElroy J, Sieracki K, Chorvat R (2008). Non-brain-penetrant CB1 receptor antagonists as a novel treatment of obesity and related metabolic disorders. Obesity 16: S47.
  • McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ et al. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14: 583588.
  • McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005). The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) 180: 286293.
  • McLaughlin PJ, Qian L, Wood JT, Wisniecki A, Winston KM, Swezey LA et al. (2006). Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 83: 396402.
  • Madsen AN, Jelsing J, Van De Wall EH, Vrang N, Larsen PJ, Schwartz GJ (2009). Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 449: 2023.
  • Makriyannis A, Vemuri VK, Thotapally R, Olszewska T (2010). International Patent Application. No: PCT/US09/01054.
  • Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530534.
  • Morse KL, Fournier DJ, Li X, Grzybowska J, Makriyannis A (1995). A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci 56: 19571962.
  • Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C et al. (2008). Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57: 29772991.
  • Onaivi ES, Carpio O, Ishiguro H, Schanz N, Uhl GR, Benno R (2008). Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci 1139: 426433.
  • Parker LA (2003). Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31: 165172.
  • Parker LA, Rana SA, Limebeer CL (2008). Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62: 198209.
  • Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ (2003). Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 550: 149158.
  • Paulino G, Barbier de la SC, Knotts TA, Oort PJ, Newman JW, Adams SH et al. (2009). Increased expression of receptors for orexigenic factors in nodose ganglion of diet-induced obese rats. Am J Physiol Endocrinol Metab 296: E898E903.
  • Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, Abellan G et al. (2006). Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21. Neuropharmacology 51: 358366.
  • Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR et al. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227234.
  • Randall PA, Vemuri VK, Segovia KN, Ferreris Torres E, Hosmer S, Nunes EJ et al. (2010). The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. 2010 Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC (in press).
  • Riedel G, Fadda P, Killop-Smith S, Pertwee RG, Platt B, Robinson L (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156: 11541166.
  • Rock EM, Benzaquen J, Limebeer CL, Parker LA (2009). Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav 91: 537541.
  • Rosenstock J, Hollander P, Chevalier S, Iranmanesh A (2008). SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31: 21692176.
  • Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007). Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91: 383388.
  • Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK et al. (2008). The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33: 946955.
  • Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G et al. (2010). Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest In press.
  • Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003). Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566G576.
  • Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167: 103111.
  • Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA (2009). Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology (Berl) 206: 155165.
  • Yamada K, Onoda Y (1993). Comparison of the effects of T-1815, yohimbine and naloxone on mouse colonic propulsion. J Smooth Muscle Res 29: 4753.